Pain in Amyotrophic Lateral Sclerosis: A Neglected Aspect of Disease by Handy, Chalonda R. et al.
Hindawi Publishing Corporation
Neurology Research International
Volume 2011, Article ID 403808, 8 pages
doi:10.1155/2011/403808
Review Article
Painin Amyotrophic LateralSclerosis:
A Neglected Aspect ofDisease
ChalondaR.Handy,ChristinaKrudy,NicholasBoulis, and ThaisFederici
Department of Neurosurgery, Emory University, 101 Woodruﬀ Circle, Room 6339, Atlanta, GA 30322, USA
Correspondence should be addressed to Thais Federici, tfederi@emory.edu
Received 11 November 2010; Accepted 6 March 2011
Academic Editor: Changiz Geula
Copyright © 2011 Chalonda R. Handy et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive loss of motor neurons, muscle
wasting, and respiratory dysfunction. With disease progression, secondary symptoms arise creating new problematic conditions
for ALS patients. Amongst these is pain. Although not a primary consequence of disease, pain occurs in a substantial number of
individuals. Yet, studies investigating its pathomechanistic properties in the ALS patient are lacking. Therefore, more exploratory
eﬀorts into its scope, severity, impact, and treatment should be initiated. Several studies investigating the use of Clostridial
neurotoxins for the reduction of pain in ALS patients suggest the potential for a neural speciﬁc approach involving focal drug
delivery. Gene therapy represents a way to accomplish this. Therefore, the use of viral vectors to express transgenes that modulate
the nociceptive cascade could prove to be an eﬀective way to achieve meaningful beneﬁt in conditions of pain in ALS.
1.Introduction
Amyotrophic lateral sclerosis (ALS) is a progressively lethal
motorneurondisorder that aﬀectsroughly2in100,000indi-
viduals each year [1–3]. Commonly referred to as Lou
Gehrig’s disease, ALS is characterized by degeneration of
primary motor neurons in the cortex, brainstem, and spinal
cord. The amyotrophy (atrophy of muscle ﬁbers) leads to
muscularparalysis due to loss of innervating motor neurons.
The lateral sclerosis typical of the disease refers to the upper
motor neuron axonal loss, the hardening of corticospinal
tracts, and the resultant gliosis [4, 5]. These changes can lead
to a number of debilitating conditions that reﬂect aberrant
functioning in both upper and lower motor neurons.
Primary symptoms of ALS include muscle weakness and
atrophy, spasticity, speech disturbances, poor management
of oral secretions, diﬃculty in swallowing, and respiratory
insuﬃciencies that usually result in death. These character-
istic features of ALS are also accompanied by a number of
secondaryconditionsthatcanbejustasburdensomeasthose
symptoms directly associated with the disorder. Amongst
these indirect complications related to the disease is pain.
Although not generally associated with ALS, pain has been
reported to occur in nearly 70% of ALS patients at some
time during the course of the disease [6–8]. Moreover,
the frequency of pain seems to be directly proportional
to disease progression [7]. Devastatingly, pain is one of
the most overlooked, understudied, and poorly managed
features of the disorder. No randomized, controlled drug
trials have been conducted to investigate pain in ALS, nor
have any published observational studies been performed
to determine the most eﬀective therapies for ALS pain
treatment. Moreover, a recent comprehensive review of ALS
literature cited fewer than 10 case series that described drug
therapyforALSpainmanagement[9].Thescarcityofstudies
directed towards proper pain evaluation and management
suggeststhatin theALSpatient,painisunderratedandcould
be frequentlyundertreated, begging the need for more inves-
tigations into the prevalence, pharmacological approaches,
and pathomechanisms of this important aspect of motor
neuron disease.
2.PaininALS
Pain is described as an unpleasant sensory and emotional
experience in response to noxious stimuli, tissue injury, or2 Neurology Research International
trauma. Pain can be acute or chronic depending on its
duration and the presence of structural and/or functional
abnormalities that aﬀect how nerves transmit nociceptive
information to the central nervous system [10–13].
Although not considered to be a primary consequence
of ALS, pain occurs in a substantial number of individuals.
Yet, studies investigating the pathomechanistic properties of
this condition and the most eﬀective means for achieving
nociceptive control in the ALS patient are lacking. Even with
the evolution of science regarding potential pain therapeu-
tics, very little eﬀort has been made to understand how these
agentsarerelevantinthecontextofALSpain.Pain,therefore,
shouldberecognizedasanimportant aspectofALSpalliative
care.
2.1. Musculoskeletal Pain. Both transitory acute pain and
persistent chronic pain have been reported in ALS. This pain
is primarily the result of inactivity and/or the presence of
jointinﬂammation thatcreatespainatthepointsofpressure.
Pain in ALS most frequently involves musculoskeletal pain
that occurs in the back, legs, arms, shoulder, and neck.
Althoughtheetiologyofthispainisnotwell understood,itis
known that musculoskeletal pain in ALS develops secondary
tomuscleatrophyanddecreasedmuscletone.Itcanberepre-
sentative of damage to bones, tendons, ligaments, joints,
nerves, or the aﬀected muscle itself. An imbalance in this
intricate network can greatly aﬀect muscle coordination,
strength, and function. It has been documented that muscle
denervation, paralysis, and disuse can aﬀect the nerve con-
duction properties of muscle aﬀerents [14–16]. It also seems
likely that chronic muscle wasting in ALS and the resultant
pathology could have drastic eﬀects on the nociceptive
cascade.
Muscle denervation is associated with axonal sprouting
and an increase in size of surviving motor units [14, 16,
17]. These changes in structural anatomy might produce a
pathophysiological condition that results in pain [8]. Thus,
one could envision that the series of events that promote the
development of musculoskeletal pain in ALS would involve
the following steps. Muscle wasting would incite collateral
axonal sprouting that enhances the surviving units and
creates a larger endplate zone, resulting in less synchronized
motorunitactionpotentials.Thiswouldleadtoaprogressive
dissociation of the mechanical and electrical properties of
the muscle that worsen over time. This alteration in muscle
coordination and force generation properties (onset, ampli-
tude, duration, and polyphasic potentials) causes abnormal
stress on the ligaments, tendons, and joints [8, 18–21].
These excessive strains could result in microtrauma to the
muscle, resulting in low levels of inﬂammation that can later
have compounding eﬀects due to insuﬃcient healing of the
aﬀected tissues. Repetitive bouts of injury due to continual
muscle wasting and decreased strength, coordination, and
tone can gradually allow for pain development. Moreover,
changes in posture, poor body mechanics, and prolonged
immobility (all characteristic of ALS) can result in spinal
alignment problems and muscleshortening, thereby creating
a more painful condition.
2.2. Muscle Cramping. Although musculoskeletalpain seems
totypicallyarise during thelatestagesofALS,which suggests
it is a cumulative event, cramps and fasciculations are more
frequent at initial stages. Cramps can be extremely painful
and occur in any muscle. Nevertheless, these excruciat-
ing conditions are seldom presenting symptoms. In fact,
although many patients experience this symptom some
monthsbeforetheonsetofmuscleweakness,concernregard-
ing these muscle fasciculations is only made after diagnosis
[5] .T h u s ,t h i si saf e a t u r eo fA L St h a ti so f t e ni g n o r e d .
Cramping can be exacerbated by cold weather or decreased
circulation caused by maintaining the muscle in the same
position for an extended period of time. With time, cramps
become less severe, however. At later stages of ALS, as the
disease progresses to complete paralysis, nerve cells lose the
ability to stimulate muscle contractions.
2.3. Spasticity. Spasticity is another common feature of ALS.
By deﬁnition, spasticity is a velocity-dependent form of
hypertonia marked by an increase in tonic stretch reﬂexes
[22, 23]. The hyperactive stretch reﬂexes associated with
spasticity are due to abnormal proprioceptive input in
the spinal cord. However, this imbalance in supraspinal
inhibitory and excitatory inputs can also perturb the noci-
ceptive reﬂexes resulting in ﬂexor and extensor spasms [23].
Muscle spasms in ALS are usually due to changes in upper
motor neurons of the motor cortex. This distortion in upper
motor neuron processing can produce the primitive reﬂex,
Babinski sign, which is one of the most important features
of clinical neuropathy [24]. Spasticity itself is not always
painful, but it can induce painful cramps, cause muscle
fatigue, or alter manual dexterity. Furthermore, spasticity
can have musculoskeletal consequences due to involuntary
mobilization of stiﬀ joints, muscle contractures, pressure
pain, such as shoe agitation due to striatal toe of Babinski
sign or even decubitus ulcers due to immobility and skin
breakdown in ﬂexor creases [25–28]. All of these muscle
hyperactivity-induced changes can distort musclemechanics
to a degree that substantially alter posture, range of motion,
ambulation, and gait, thus creating new sources of pain [29].
Although the literature concerning the relationship
between stride parameters and nociception is lacking, it
has been shown that gait analysis is a useful assessment of
function in chronic pain suﬀerers [30–32]. Changes in gait
have been observed in ALS, and alterations of gait dynamics
would result from muscle weakness, decreased tone, and
endurance as well as alterations in motor cortex excitability,
muscle ﬁber conduction, velocity, and mechanical eﬃciency
[33, 34]. ALS characteristic upper motor neuron pathology
can aﬀect all of these factors in addition to promoting
spasticitybylimitingbrainstemcontrolofthevestibulospinal
and reticulospinal tracts.
3.CurrentALSPainTherapies
There is no cure for ALS. Likewise, there is no single most
eﬀective therapy for ALS-associated pain. Palliative care for
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thataddressesnotonlytheoropharyngeal,respiratory, nutri-
tional, psychological, and motor functional concerns of the
patient, but also the disabling nociceptive features of the
disorder as well.
Again, most ofthepain associated with ALSis believedto
be due in large part to immobility. Physiotherapy, stretching,
and range of motion exercises are used in combination
with pharmacotherapies to prevent contractures and reduce
cramping, spasticity, and pain. In ALS, routine moderate
resistance exercise has been shown to improve static force
in muscle groups and slow functional decline. Joint mobi-
lization techniques as well as frequent sustained lengthening
of aﬀected muscle groups are also eﬀective in reducing
some of the musculoskeletal pain, spasticity, and cramping
experienced by ALS patients [35, 36].
Drug therapies administered to ALS suﬀerers early on
in the course of the disease are directed toward control of
fasciculations and muscle cramps. Mild muscle twitches
are often treated with vitamin E or magnesium [25, 35].
However, as the cramps progress in intensity and duration,
carbamazepine, quinine sulphate, or phenytoin may also
be given [35]. With time and the development of spas-
ticity, myorelaxants such as baclofen, a γ-amino-butyric
acid (GABA) analog that facilitates spinal motor neuron
inhibition, are employed [37, 38]. Oral baclofen is usually
administered 2-3 times a day in a 10mg dose, but can be
titrated up to a 4 times per day—20mg dose if necessary
[36, 39]. Higher doses can produce problematic side eﬀects
such as sedation, weakness, and fatigue [36]. For these
reasons, baclofenis often administered intrathecally to evade
these adverse reactions. Other drugs used to treat spasticity
in ALS include tizanidine, dantrolene sodium, diazepam,
and memantine [25, 35, 39, 40]. Moreover, a combination
of drugs may also be administered considering the unique
mechanistic properties of these pain therapeutics. Although
eﬃcacious in oﬀering some degree of symptomatic relief
for pain, it is also necessary to mention that like baclofen,
in excess, these myorelaxants can increase muscle weakness,
further complicating the disease process in ALS.
As the disease progresses and mobility decreases, pain
becomes more common due to altered tone around joints,
stiﬀness, and atrophy. To treat pain in advanced stages of
ALS, nonsteroid anti-inﬂammatory drugs (NSAIDS) may
also be given for moderate to severe pain. If necessary,
narcoticanalgesics are administered toachieveanalgesia. Ina
h o s p i c es t u d yw h e r em o r et h a n8 0 %o ft h ep a t i e n t sr e c e i v e d
the therapy at least once a day, opioids eﬀectively oﬀered
beneﬁt to about 70% of the patients with advanced motor
neuron disease [41, 42]. Despite these analgesic eﬀects,
opioids are associated with a number of side eﬀects that
can dramatically complicate ALS characteristic conditions.
Narcotics can depress respiration, decrease airway protec-
tion, suppress cough, obstruct defecation, cause sedation,
or result in physical dependence. Nevertheless, historically
they have been the most eﬃcacious agents used to oﬀer
meaningful relief in conditions of intractable pain. However,
due to unwanted side eﬀect attention has now been turned
towards therapies that oﬀer focal delivery of agents known
to modulate the nociceptive cascade. In fact, intramuscular
botulinumtoxin(BoNT)injectionshavebeen usedtoreduce
spasticity in ALS despite skepticism concerning muscle
delivery in cases of continual muscle wasting [43, 44]. Yet,
these new approaches to nociceptive control oﬀersubstantial
promise for ALS pain.
4.Gene Therapyasa PotentialTherapeuticfor
ALSPain
The use of intramuscular injections of BoNT for temporary
pain relief in ALS has set the stage for the evaluation of
lasting therapiestominimize ALS-associated painconditions
and revolutionized the treatment of focal spasticity. These
studies demonstrated that focal injection of the Clostridial
toxin into a pathologic microenvironment is still eﬀective in
combating aberrant nociceptive signaling despite persistent
muscle wasting. Nevertheless, certain challenges still remain
relevant to BoNT intramuscular administration in ALS
patients. In particular, the transient nature of BoNT, lasting
only a few months, creates a need for repeat application. Of
greater concern is the observation of generalized weakness
following BoNT administration in isolated cases [43–45].
Collectively, these studies suggest a need for more impressive
means of modulating ALS pain transmission. Nevertheless,
these studies present the argument for ﬁnding ways to
stabilize BoNT expression to produce lasting results.
Of the most exciting technologies that could be used to
achieve lasting results is the employment of gene therapy to
facilitate antinociceptive transgene expression. Gene therapy
often involves the use of viral vectors to drive robust expres-
sion of a gene of interest. The gene is ﬂanked by regulatory
elements necessary for transcription and promoters that
can be optimized to drive gene expression in restricted cell
types or at selected time points. In the context of pain, a
number of transgenes have been evaluated to regulate pain
pathogenesis. Gene expression in these studies has involved
the use of vectors derived from adenovirus, adenoassociated
virus (AAV), lentivirus as well as herpes-simplex virus
(HSV) [46, 47]. The unique tropism, cloning capacity and
expression proﬁles of these vectors determine their ability to
eﬀectively modulate nociceptive signaling. Although a wide
body of literature exists describing the use ofviral vectorsfor
conditions of chronic pain, little attention has been paid to
how this is related in the context of ALS-pain [10, 11, 48–
53]. Therefore, it is necessary to establish translational links
between therapiesshown to be eﬀectivein ALS pain and how
targetedgeneexpression using agentsknown tomediatepain
perception and transmission could oﬀer substantial beneﬁt
in ALS-related nociception.
4.1. Potential Transgenes. GABA is a major inhibitory neuro-
transmitter and the use of the GABA analog baclofen is the
foremost therapy for ALS spasticity [35, 36, 39]. Although
ALS-associated spasticity can be adequately controlled with
baclofen, as stated earlier, disease progression requires
increased dosage that can result in drug tolerance. Moreover,
the use of implanted pumps for continual drug delivery
carries the risk of infection, complication, or malfunction.4 Neurology Research International
Therefore, the use of viral vectors for one time administra-
tion of transgenes that result in GABA overproduction can
have substantial advantages over currently used approaches.
One of the most widely studied genes for GABA over-
production is glutamic acid decarboxylase (GAD). The rate-
limiting enzyme required for GABA production is GAD,
which convertsglutamatetoGABA.Viralvector-drivenGAD
expression has been shown to have antinociceptive eﬀects.
Preclinical studies have demonstrated the beneﬁts of gene
delivery of GAD for the attenuation of pain in rodents using
adenoviral, AAV, and HSV vectors [54–56]. This approach
seems feasible forhuman application considering the clinical
trials centered on the application of AAV-GAD for the
treatment of overexcitation due to Parkinson disease [57–
59].Accordingly,clinicalgradeHSVvectorsbearingGADare
currently being evaluated in rodent models of neuropathic
pain [48, 53]. If successful, these studies could advance to
clinical investigations into the safety and eﬃcacy of HSV-
GAD for attenuating pain in individuals with diabetic
neuropathy [48]. Therefore, it is logical to assume that focal
gene transfer of GAD could oﬀer substantial beneﬁt for
spasticity in ALS.
The use of Clostridial neurotroxins has been shown to be
beneﬁcialforpain instudiesinvolving focaldeliveryofBoNT
[43–45]. However, this property could be greatly enhanced
by coupling the control of ALS pain with viral vector tech-
nology. Gene delivery of BoNT could have lasting eﬀectsthat
evade the need for repeat administration. Alternatively, the
use of bacterial toxins known to aﬀect GABA transmission
could also be just as beneﬁcial. Speciﬁcally, our laboratory
has demonstrated the use of the light chain (LC) fragment
of the Clostridial tetanus neurotoxin in inhibiting synaptic
function, thereby suppressing glutamatergic signaling [60].
Although these studies were not done in the context of
pain, they demonstrated for the ﬁrst time the beneﬁts of
viral vector driven LC expression to modulate synaptic
activity in spinal motor neurons. Using adenoviral vectors to
d r i v eL Ct r a n s g e n ee x p r e s s i o n ,w ew e r ea b l et od e m o n s t r a t e
these changes without neuronal cell death. We were also
able to achieve substantial outcome measures indicating a
profound inﬂuence on neurotransmitter release based on
lumbar injections into the spinal cords of rats. We were also
able to demonstrate that we could successfully aﬀect the
GABAergic system by adenoviral delivery of LC to the brain
stem without altering surrounding CNS structures [60, 61].
Considering the brainstem derived pattern of activity that
underlies painful spasticity in ALS patients, these studies
suggest that an eﬀective, neuronal speciﬁc approach such as
this could be a viable approach for spasticity in ALS.
Gene therapy also oﬀers hope for musculoskeletal pain
and pain associated with advanced ALS disease. Certain
peripheral and spinal neurons are involved in mediating
musculoskeletal pain. Muscle injury or joint trauma can
increase nociceptive processing, and if inﬂammation ensues,
peripheral nociceptors can become sensitized, resulting in
increased neurotransmitter release in the dorsal horn of the
spinalcord[62–65].Thissensitizationofteninvolvestheacti-
vation of N-methyl-D-aspartate (NMDA) receptor signaling
that leads to excitation of primary aﬀerents at the site of
injury, thereby potentiating the pain response [62, 63, 66].
These eﬀects have been linked to conditions associated with
the development and maintenance of arthritis [62, 63, 66–
68]. Admittedly, arthritis is not a common condition found
in the ALSpopulation and cases where there is coexistence of
the two disorders are probably due only to chance. However,
an understanding of treatment approaches for chronic in-
ﬂammatory pain conditions can provide valuable insight
into how eﬀective therapies can be applied to more acute
pain conditions associated with impaired joint function in
ALS. Interestingly, it has been shown that viral vector-
mediated NMDAreceptorelimination candecreasepain-like
behaviors in mice [69]. Taken together, these studies suggest
that ALS musculoskeletal pain can be attenuated by targeted
inhibition of NMDA receptor signaling.
Opioids are the most commonly used treatment for pain
ingeneral.However,forALSpain,opioidsare notcommonly
prescribed until very late stages of the disease. Many opioid
peptidesexist.Allofwhich resultfromoneofthreeprecursor
peptides: proenkephalin-A, prodynorphin, or propiomela-
nocortin [70]. Proenkephalin-A, the only one found in the
spinal cord, is responsible for producing the antinociceptive
peptides met and leu-enkephalin. The anatomical distribu-
tion and receptorassociation properties of these peptides are
responsibleforthepaininhibitorypropertiesofopiatedrugs.
Transgenic expression of opiate peptides has been shown
to decrease pain behaviors in laboratory and clinical studies
ofchronic pain.Speciﬁcally,HSV-directedexpression ofpro-
enkephalin has proven to be eﬀective in attenuating both
chronic and acuteconditionsusing animal models ofinﬂam-
matory, neuropathic, and bone cancer pain [53, 71–74].
Furthermore, a phase I study based on these preclinical
ﬁndings is currently being conducted to evaluate the safety
of a replication-defective HSV vector for eﬀective delivery
ofpreproenkephalinfollowing intradermal vectordeliveryin
patients with intractable cancer pain [48, 49]. If successful,
these studies will allow for phase 2 trials aimed at deter-
mining the eﬃcacy of HSV-mediated preproenkephalin in
individuals with focal arthritic pain [48].
4.2. Therapeutic Application Considerations. Although gene
therapyoﬀersapracticalapproachtoaddressing paininALS,
itisonlyaworthy pursuitifithas substantialadvantages over
commonly used pharmacologic strategies. Due to the lack
of literature in the context of ALS describing investigations
into pain incidence, eﬀects on quality of life, origin and
maintenance, or the tolerability and eﬃcacy of drugs to
circumvent pain syndromes in the ALS population, it is
diﬃcult to determine the speciﬁc problems associated with
pain treatment in ALS. Nevertheless, an appreciation of the
current issues associated with pain management in chronic
disease oﬀerssubstantial cluesas tothecriteria thatasuitable
alternative treatment approach must meet.
A novel pain therapy for ALS would have to meet certain
criteria. It would have to be safe and well tolerated with
minimal oﬀ-target eﬀects. It would be eﬀective in mod-
ulating the nociceptive cascade to produce lasting eﬀects,
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the therapy as is the case with pharmacologic agents. Gene
therapy for pain in ALS should be adjustable and reversible.
Several inducible systems have been developed to allow for
regulated expression of transgenes [75–78]. To do so, the
transgene of interest is expressed under the control of an
inducible promoter that activates or represses transcription
in the presence of biotic or abiotic factors. Such is the case
with the tetracycline responsive promoter system where in
the presence of doxycycline, promoter activity can be mod-
ulated to induce or hinder transgene expression due to its
association with doxycycline and the tetracycline responsive
transactivator protein complex.This systemcan allow forthe
regulated expression of antinociceptive transgenes as needed
bythepatient.Also,becausedoxycylinepenetratestheblood-
brain barrier and cerebral spinal ﬂuid, it can be applied to
control CNS gene expression as well [79, 80].
Careful consideration of delivery parameters is also im-
portant for determining if gene therapy is a suitable method
for treating pain in ALS. Because recurrent pain usually
suggests aberrant neural conduction properties in the spinal
cord, treatment applications should involve a way to tar-
get spinal motor neurons. Direct spinal cord delivery of
transgene, although risky, is a feasible treatment strategy.
This approach carries with it additional challenges, however.
There is the need for stable, long-term gene expression in
that repeat administration would be impractical. There is
also the concern that spinal cord injections could create
further damage to an already toxic microenvironment due
to surgery-associated spinal cord trauma.
Remote delivery oftherapeuticvectorsmay proveto have
considerable advantages over direct spinal cord injection.
Enthusiasm for muscle delivery of viral vectors for the
retrograde delivery of therapeutic genes is centered on the
fact that remote gene delivery of insulin-like growth factor
1 (Igf-1) has been shown to eﬀectively achieve retrograde
transport and increase survival in an animal model of ALS
[81].These resultssuggeststhatdespitethediebackofmotor
neurons, a pathological feature that has been associated with
ALS, suﬃcient retrograde transport can still be achieved by
the spared neural circuits that remain intact.
Skeletal muscles are innervated by ﬁbers from motor
neurons. After peripheral inoculation, certain factors includ-
ing Clostridial tetanus toxin are able to undergo retrograde
transport to the CNS. It is important to note that the use
of tetanus toxin for neuronal targeting presented here is not
the same as that which has already been discussed in the
context of its light chain fragment. Full-length tetanus toxin
is composed of both a light and a heavy chain. Although
the light chain is the means through which it exerts its
protease activity, the heavy chain allows for cell binding and
entry. Therefore, the coupling of the retrograde transport
properties of the heavy chain with that of transgenes known
to modulate nociception could prove to be an eﬀective
treatment approach for ALS pain. Thus, this could oﬀer a
means to target spinal cord neurons by muscle injection.
Admittedly, considerable laboratory investigations into
the generation and the use of these approaches have not
been made. While the possibility of their application to the
patient population aﬀected by pain is a long way oﬀ,t h e r e
are, however, alternative means for retrograde transport
currently available. One of the unique features of HSV is
that it has evolved a mechanism for retrograde transport.
Moreover,thesevectorscanbeproducedtoclinicallyrelevant
titers necessary for large-scale human therapy. Likewise,
these vectors are currently being employed clinically in trials
investigating potential ways to combat pain in advanced
diseases [48, 49].
5.Conclusions
Pain inALSisacommonlyoverlooked,understudied,under-
rated,andpotentiallyundertreatedaspectofthedisease. This
problem is not unique to ALS, however. This is due in large
part to the traditional approaches that have been taken to
evaluate pain in isolation of other pathologic conditions.
This can have devastating eﬀects on patients that greatly
diminish quality of life, in that pain has been shown to be
criticalbarriertoadequatecareamongst thedying. Inastudy
to investigate these concerns, family respondents of chroni-
callyillindividualsreportedthatatthetimeofdeath,patients
experience moderate to severe pain [82]. Interestingly, this
observation was highest amongst hospitalized individuals.
Family respondents also identiﬁed that there was a need for
more guidance and support to deal with the pain of the
patient and nearly 30% of respondents believed that medical
staﬀ was reluctant to medicate [82]. These pain-related
barriers to medical care echo earlier reports investigating
pain among the elderly where nearly 50% of dying patients
lack adequate pain treatment at the time of death [82, 83].
There are many reasons for the improper management of
pain in ALS.It is the consequenceof a number of factors that
may include failure of the physician to recognize pain in the
ALS patient. In order for the pain to be treated, it has to be
reported. Since pain is not a primary consequenceof the dis-
easeandnotusuallyassociated withALS,routinepainassess-
ments are seldom done. Another reason for inadequate pain
management could be reluctance of the physician to admin-
ister pain medications. This could be out of fear of scrutiny
from medical regulatory authorities as has been reported
in studies investigating hospital staﬀ response to increased
reports of pain amongst the dying [84]. Moreover, patients
lack the tendency to report pain in many cases. This could
reﬂect a belief that pain is a normal aspect of the disease as
has been the case with unreported pain amongst the elderly
or individuals with cancer [85, 86]. Patient reluctance to
report pain couldalso be derivedoutoffearthat theimplica-
tion of a pain treatment regimen might divert the physician’s
attention away from treatment of the primary consequences
of the disease [86, 87]. This is devastating, considering pain
is a highly treatable condition, and poor pain management
only intensiﬁes patient suﬀering and has drastic eﬀects on
the emotional and social well-being of ALS patients [7].
Proper pain management in ALS should involve a multi-
disciplinary approach just as is the case with other aspects
of the disease. Considering half of ALS patients experience
pain involving more than one type, no rigid treatment
program that involves the sole use of a single agent should
be employed to treat ALS-associated pain conditions [7].6 Neurology Research International
Hence, a patient-speciﬁc approach should be taken to
address pain in ALS palliative care.
A number of therapies centered on modulation of the
inhibitory GABAergic system have proven to be eﬀective in
treating ALS pain. Baclofen is widely used to treat spasticity,
and its use is commonly implemented into the treatment
plan during early stages of the disease. With disease pro-
gression, pain frequency and intensity can increase, creating
t h en e e df o rt h eu s eo fn a r c o t i ca g e n t s .O p i o i d sh a v ep r o v e n
to be eﬀective in providing pain relief in advanced disease.
Nevertheless, these therapies lack the ability to induce long-
term lasting eﬀects without constant administration.
Gene therapy for pain associated with ALS could have
substantial promise. Hallmark studies demonstrate the abil-
ityofviralvectorstoattenuatepainbymodulatinginhibitory
regulatory systems. Moreover, in advanced disease states,
targetedgene deliveryofopiatepeptidescanbeused to mod-
ulate ALS-associated nociception. Therefore, the use of viral
vectors could prove to be quite advantageous for treating
pain, setting the stage for a new class of drugs eﬀective at
alleviating conditions observed in patients with ALS.
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